Artesunate in Treating Patients with High Grade Cervical Intraepithelial Neoplasia

Inclusion Criteria

• Patients with high-grade cervical intraepithelial lesions (CIN2/3) confirmed by colposcopy and biopsy
• Patients who have measurable disease after diagnostic biopsy
• Patients who weigh >= 50 kg
• Patients who are HPV-positive by deoxyribonucleic acid (DNA) test
• Patients who are able to give informed consent
• Patients who are immunocompetent
• Patients who are not pregnant; committed to using adequate contraception through week 15 if of childbearing age; condom use will be encouraged
• Patients who have the ability to collaborate planned follow-up

Exclusion Criteria

• Patients with cytologic evidence of glandular dysplasia
• Patients with cytologic evidence of adenocarcinoma in situ
• Patients who are taking immunosuppressive medication
• Patients with concurrent malignancy except for nonmelanoma skin lesions
• Patients who have an active autoimmune disease or history of autoimmune disease requiring medical treatment with systemic immunosuppressants, including: inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemic, or immune thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus (SLE), and Sjogren’s syndrome, sarcoidosis; asthma or chronic obstructive pulmonary disease (COPD) that does not require systemic corticosteroids or routine use of inhaled steroids is acceptable